03855nam 2200853z- 450 991055739050332120231214133456.0(CKB)5400000000041993(oapen)https://directory.doabooks.org/handle/20.500.12854/77077(EXLCZ)99540000000004199320202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierMultimodality Treatments in Metastatic Gastric CancerBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (162 p.)3-0365-2592-0 3-0365-2593-9 Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.Medicinebicsscadvanced gastric cancerprecision medicinenew drug developmentgastro-oesophageal cancermutational concordanceexome sequencingformalin fixed paraffin embeddedbiomarkersgastric cancermetastaticbody compositionsarcopeniavisceral fat areasubcutaneous fat areaoutcometoxicityliver metastasisconversion surgeryhepatectomystage iv gastric cancerimmune checkpoint inhibitorsEpstein Barr Virustumor mutational burdenmicrosatellite instabilitypredictive biomarkersCAR T cell therapyvaccinesnutritional statusmetastatic gastric cancertarget therapybone flarestage IVtreatmentRANK-Lliquid biopsycirculating tumor cellcfDNActDNAepithelial-mesenchymal transitionresistance to treatmentHER2-inhibitionVEGFR-inhibitionimmunotherapyresponse monitoringMedicinePetrillo Angelicaedt1295530Petrillo AngelicaothBOOK9910557390503321Multimodality Treatments in Metastatic Gastric Cancer3023583UNINA04217nam 22007455 450 991048438150332120200920115342.03-662-43868-210.1007/978-3-662-43868-8(CKB)3710000000291532(EBL)1967775(OCoLC)908087784(SSID)ssj0001386396(PQKBManifestationID)11830272(PQKBTitleCode)TC0001386396(PQKBWorkID)11374135(PQKB)10993570(DE-He213)978-3-662-43868-8(MiAaPQ)EBC1967775(PPN)183093755(EXLCZ)99371000000029153220141119d2015 u| 0engur|n|---|||||txtccrChinese Merger Control Law An Assessment of its Competition-Policy Orientation after the First Years of Application /by Tingting Weinreich-Zhao1st ed. 2015.Berlin, Heidelberg :Springer Berlin Heidelberg :Imprint: Springer,2015.1 online resource (408 p.)Munich Studies on Innovation and Competition,2199-7462 ;2Description based upon print version of record.3-662-43867-4 Includes bibliographical references.1. Introduction -- 2. Economic Background of Competition Policy in China -- 3. Historical Development of Chinese Merger Control Regime -- 4. Institutional Framework for Enforcement of the AML -- 5. Objectives and Policy Standards of Merger Control as Embodied in the AML -- 6. Overview of Published Decisions -- 7. Scope of Application of Merger Control Law -- 8. Merger Review Procedure -- 9. Substantive Merger Control Test -- 10. Outlook on Judicial Enforcement of Merger Control Law -- 11. Conclusion.On 1 August 2008, the Chinese Anti-Monopoly Law entered into force, introducing a comprehensive framework for competition law to the Chinese market. One set of the new rules pertains to merger control. China’s Ministry of Commerce (MOFCOM) was nominated as the authority responsible for enforcing merger control in China, and has been actively doing so ever since. Recent years have established China as one of the most important merger filing jurisdictions for cross-border mergers alongside the EU and USA. This work evaluates the Chinese merger control law regime and MOFCOM’s decision-making practice after more than five years of application. In particular, it assesses which policy goals (competition policy goals or industrial policy considerations) prevail in the written law and its application, and provides suggestions for a further improvement of the law – with the aim to develop a transparent merger control regime that promotes long-term economic growth in China.Munich Studies on Innovation and Competition,2199-7462 ;2Private international lawConflict of lawsGlobalizationMarketsInternational lawTradePrivate International Law, International & Foreign Law, Comparative Law https://scigraph.springernature.com/ontologies/product-market-codes/R14002Emerging Markets/Globalizationhttps://scigraph.springernature.com/ontologies/product-market-codes/525010International Economic Law, Trade Lawhttps://scigraph.springernature.com/ontologies/product-market-codes/R19050Private international law.Conflict of laws.Globalization.Markets.International law.Trade.Private International Law, International & Foreign Law, Comparative Law .Emerging Markets/Globalization.International Economic Law, Trade Law.340340.2340.9343.07Weinreich-Zhao Tingtingauthttp://id.loc.gov/vocabulary/relators/aut1228773BOOK9910484381503321Chinese Merger Control Law2852720UNINA